MedTrace Logo

Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome

NCT04701164 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 242

Last updated 2025-05-29

No results posted yet for this study

Summary

This study is intended to evaluate the efficacy and safety of ANX005 administered by intravenous (IV) infusion to participants recently diagnosed with Guillain-Barré Syndrome (GBS). The total duration of study participation is approximately 6 months.

Conditions

  • Guillain-Barre Syndrome

Interventions

DRUG

ANX005

Solution for intravenous infusion

DRUG

Placebo

Solution for intravenous infusion

Sponsors & Collaborators

  • Annexon, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Annexon, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-17
Primary Completion
2024-04-20
Completion
2024-04-20
FDA Drug
Yes

Countries

  • Bangladesh
  • Philippines

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04701164 on ClinicalTrials.gov